source
- Roche’s enicepatide shows dose-dependent blood sugar and weight loss in Phase 2 diabetes trialRoche reported that its injectable GLP-1/GIP dual agonist enicepatide, acquired through the Carmot Therapeutics purchase, achieved reductions in blood glucose and body weight in a Phase 2 study of…
- Compass Therapeutics to file BLA for tovecimig despite FDA call for new trialCompass Therapeutics announced it will continue pursuing a biologics license application (BLA) for its bispecific antibody tovecimig aimed at advanced biliary tract cancer, even after the FDA sugge…